170 related articles for article (PubMed ID: 15013217)
1. MYCN in neuronal tumours.
Schwab M
Cancer Lett; 2004 Feb; 204(2):179-87. PubMed ID: 15013217
[TBL] [Abstract][Full Text] [Related]
2. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
3. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.
Wang LL; Teshiba R; Ikegaki N; Tang XX; Naranjo A; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Asgharzadeh S; Shimada H
Br J Cancer; 2015 Jun; 113(1):57-63. PubMed ID: 26035700
[TBL] [Abstract][Full Text] [Related]
4. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients.
Combaret V; Audoynaud C; Iacono I; Favrot MC; Schell M; Bergeron C; Puisieux A
Cancer Res; 2002 Jul; 62(13):3646-8. PubMed ID: 12097268
[TBL] [Abstract][Full Text] [Related]
5. Keratoepithelin reverts the suppression of tissue factor pathway inhibitor 2 by MYCN in human neuroblastoma: a mechanism to inhibit invasion.
Becker J; Volland S; Noskova I; Schramm A; Schweigerer LL; Wilting J
Int J Oncol; 2008 Jan; 32(1):235-40. PubMed ID: 18097563
[TBL] [Abstract][Full Text] [Related]
6. Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncology.
Schwab M
Ann N Y Acad Sci; 2002 Jun; 963():63-73. PubMed ID: 12095930
[TBL] [Abstract][Full Text] [Related]
7. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
[TBL] [Abstract][Full Text] [Related]
8. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
9. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections.
Tsai HY; Hsi BL; Hung IJ; Yang CP; Lin JN; Chen JC; Tsai SF; Huang SF
Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898
[TBL] [Abstract][Full Text] [Related]
10. Concomitant DDX1 and MYCN gain in neuroblastoma.
Defferrari R; Tonini GP; Conte M; Papio F; Sementa AR; Valent A; Schena F; Perri P; Mazzocco K
Cancer Lett; 2007 Oct; 256(1):56-63. PubMed ID: 17611020
[TBL] [Abstract][Full Text] [Related]
11. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
[TBL] [Abstract][Full Text] [Related]
12. Integrin α4 Enhances Metastasis and May Be Associated with Poor Prognosis in MYCN-low Neuroblastoma.
Young SA; McCabe KE; Bartakova A; Delaney J; Pizzo DP; Newbury RO; Varner JA; Schlaepfer DD; Stupack DG
PLoS One; 2015; 10(5):e0120815. PubMed ID: 25973900
[TBL] [Abstract][Full Text] [Related]
13. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
[TBL] [Abstract][Full Text] [Related]
14. Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN.
Koppen A; Ait-Aissa R; Koster J; Øra I; Bras J; van Sluis PG; Caron H; Versteeg R; Valentijn LJ
Int J Cancer; 2008 Apr; 122(7):1455-64. PubMed ID: 18059033
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
Alaminos M; Gerald WL; Cheung NK
Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
[TBL] [Abstract][Full Text] [Related]
16. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
17. The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas.
Weber A; Starke S; Bergmann E; Christiansen H
Clin Cancer Res; 2006 Dec; 12(24):7316-21. PubMed ID: 17189403
[TBL] [Abstract][Full Text] [Related]
18. N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma.
Fletcher JI; Gherardi S; Murray J; Burkhart CA; Russell A; Valli E; Smith J; Oberthuer A; Ashton LJ; London WB; Marshall GM; Norris MD; Perini G; Haber M
Cancer Res; 2012 Feb; 72(4):845-53. PubMed ID: 22202125
[TBL] [Abstract][Full Text] [Related]
19. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy.
Suita S; Tajiri T; Kaneko M; Hirai M; Mugishima H; Sugimoto T; Tsuchida Y
J Pediatr Surg; 2007 Mar; 42(3):489-93. PubMed ID: 17336185
[TBL] [Abstract][Full Text] [Related]
20. The MYCN enigma: significance of MYCN expression in neuroblastoma.
Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N
Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]